Figure 6.

Gypenoside XL attenuated haptic injury in NAFLD mice. Treatments with GP extracts have no obvious effects on the body weight in NAFLD mice; treatment with Gypenoside XL 10, 20 mg/kg/day, decreased both serum ALT and AST level; Gypenoside XL could increase SOD, GSH-Px level in haptic tissues. MDA levels in NAFLD liver tissue were significantly decreased after Gypenoside XL treatment (p < 0.01) (a). The Oil Red O, H&E, and Picrosirius red staining results showed that Gypenoside XL 10 and 20 mg/kg/day could relieve haptic fat degeneration and fibrosis in NAFLD mice (b). ^#Compared with normal group p < 0.05, ^∗p < 0.05, ^∗∗p < 0.01 compared with model group.